JP2000212066A - Aqueous liquid preparation of fat-soluble material - Google Patents
Aqueous liquid preparation of fat-soluble materialInfo
- Publication number
- JP2000212066A JP2000212066A JP11325192A JP32519299A JP2000212066A JP 2000212066 A JP2000212066 A JP 2000212066A JP 11325192 A JP11325192 A JP 11325192A JP 32519299 A JP32519299 A JP 32519299A JP 2000212066 A JP2000212066 A JP 2000212066A
- Authority
- JP
- Japan
- Prior art keywords
- fat
- soluble substance
- aqueous solution
- soluble
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は脂溶性物質の含水水
性液剤、およびその製造方法に関する。The present invention relates to a water-containing aqueous solution of a fat-soluble substance and a method for producing the same.
【０００２】[0002]
【従来の技術】一般に脂溶性物質は水に対して不溶性で
あり、食品や医薬品に添加する際に分離し不均一になり
やすいという欠点がある。この点を解決するために、種
々の試みがなされている。例えば、特開昭62-250941号
公報には、天然または合成の精油、色素、ビタミン、香
料より選ばれる１種または２種以上よりなる非水溶性物
質１〜70重量部に水酸基価970以下のポリグリセリンを
モノ、ジ、トリエステル化して得られるポリグリセリン
脂肪酸エステル１〜90重量部と水0.1〜50重量部および
多価アルコール１〜90重量部を混合し可溶化することを
特徴とする可溶化液の製造法が記載されている。また、
特開昭63-23811号公報には、乳化剤を含有する油相中に
薬物を分散させ、注射用水を用いて乳化し、高圧ホモジ
ナイザーを用いて均質化して得られる医薬製剤について
開示されている。さらに、特許2734520号公報には、脂
溶性の薬理活性物質、全量の0.1〜3.0w/v％の油相成分
並びにリン脂質および非イオン性界面活性剤を必須成分
とする0.1〜20w/v％の乳化剤を2000kg/cm2以上の能力を
有する高圧乳化機を用いて乳化することを特徴とする、
平均粒子径が10nm以上40nm未満である微粒子脂肪乳剤の
製造方法が開示されている。2. Description of the Related Art Generally, fat-soluble substances are insoluble in water and have a drawback that they tend to separate and become non-uniform when added to foods and pharmaceuticals. Various attempts have been made to solve this problem. For example, JP-A-62-250941 discloses that 1 to 70 parts by weight of a water-insoluble substance composed of one or more selected from natural or synthetic essential oils, pigments, vitamins, and fragrances has a hydroxyl value of 970 or less. It is possible to mix and solubilize 1 to 90 parts by weight of a polyglycerin fatty acid ester obtained by mono-, di-, or tri-esterification of polyglycerin, 0.1 to 50 parts by weight of water and 1 to 90 parts by weight of a polyhydric alcohol. A method for producing a lysate is described. Also,
JP-A-63-23811 discloses a pharmaceutical preparation obtained by dispersing a drug in an oil phase containing an emulsifier, emulsifying with an injection water, and homogenizing with a high-pressure homogenizer. Furthermore, Japanese Patent No. 2734520 discloses a fat-soluble pharmacologically active substance, 0.1 to 3.0 w / v% of the total amount of an oil phase component, and 0.1 to 20 w / v% containing a phospholipid and a nonionic surfactant as essential components. Emulsifying the emulsifier using a high-pressure emulsifier having a capacity of 2000 kg / cm 2 or more,
A method for producing a fine particle fat emulsion having an average particle diameter of 10 nm or more and less than 40 nm is disclosed.
【０００３】[0003]
【発明が解決しようとする課題】しかしながら、このよ
うにして得られた製剤は、安定性や均一性、透明度の面
から見ると未だ十分ではなく、さらに技術的に改良する
必要があるものと考えられる。したがって、本発明は長
期間に渡って均一性が保たれ安定性が高く、しかも透明
度の高い脂溶性物質の水性液剤およびその製造方法を提
供することを目的とする。However, the preparation obtained in this way is not yet sufficient in terms of stability, uniformity and transparency, and it is considered that there is a need for further technical improvements. Can be Accordingly, an object of the present invention is to provide an aqueous liquid preparation of a fat-soluble substance which has high stability while maintaining uniformity over a long period of time and high transparency, and a method for producing the same.
【０００４】[0004]
【課題を解決するための手段】これらの状況から本発明
者らは、鋭意研究を進めた結果、脂溶性物質に乳化剤、
多価アルコールを加え均一化した後、高圧処理すること
によって上記の課題が解決できることを見出し、本発明
を完成させた。すなわち本発明は脂溶性物質を乳化剤、
多価アルコールおよび水を攪拌混合した後、高圧処理す
ることを特徴とする脂溶性物質水性液剤、およびその製
造方法である。Means for Solving the Problems Under these circumstances, the present inventors have conducted intensive studies and found that an emulsifier, a fat-soluble substance,
The inventors have found that the above problems can be solved by high-pressure treatment after adding and homogenizing a polyhydric alcohol, and completed the present invention. That is, the present invention is a fat-soluble substance emulsifier,
An aqueous solution of a fat-soluble substance, which comprises subjecting a polyhydric alcohol and water to stirring and mixing, followed by high-pressure treatment, and a method for producing the same.
【０００５】[0005]
【発明の実施の形態】本発明では、脂溶性物質にステア
リン酸デカグリセリル、レシチン、リゾレシチン等の乳
化剤、プロピレングリコール、ソルビトール等の多価ア
ルコールおよび水を加え、ホモミキサー、コロイドミル
等で均一化した後に、高圧ホモジナイザーを用いて高圧
処理して水性液剤を調製する。In the present invention, an emulsifier such as decaglyceryl stearate, lecithin and lysolecithin, a polyhydric alcohol such as propylene glycol and sorbitol and water are added to a fat-soluble substance, and the mixture is homogenized with a homomixer, colloid mill or the like. After that, the aqueous solution is prepared by high-pressure treatment using a high-pressure homogenizer.
【０００６】本発明における脂溶性物質は医薬品、化粧
品、食品等の原料物質として使用されるものであればい
ずれでもよく、特に限定されない。好ましくはテプレノ
ン、ユビデカレノン、クロタミトン、ジフェンヒドラミ
ン、リドカイン、ヒノキチオール等の薬剤として使用さ
れる脂溶性化合物、ビタミン類、エステル油、鉱物油、
ＤＨＡ、肝油、魚油、大豆油、ゴマ油、オリーブ油、月
見草油、スクワラン、ヒマワリ油、しそ油等の油脂、カ
ロチン、アナトー色素等の油溶性色素、ビタミンＥ、Ｂ
ＨＴ、γ−オリザノール等の酸化防止剤、メントール、
シオネール、ローズ油等の着香料、食品や健康食品、化
粧品、医薬品等に使用される物質である。さらに好まし
くはビタミンＡ、Ｄ、Ｅ、Ｋ等の脂溶性ビタミン、また
はこれらの混合物である。脂溶性物質の含有量は通常１
〜40％、好ましくは5〜30％である。The fat-soluble substance in the present invention may be any substance as long as it is used as a raw material for pharmaceuticals, cosmetics, foods and the like, and is not particularly limited. Lipid-soluble compounds, vitamins, ester oils, mineral oils, preferably used as pharmaceuticals such as teprenone, ubidecarenone, crotamiton, diphenhydramine, lidocaine, hinokitiol,
DHA, liver oil, fish oil, soybean oil, sesame oil, olive oil, evening primrose oil, squalane, sunflower oil, oils and fats such as perilla oil, carotene, oil-soluble pigments such as annatto pigment, vitamin E, B
Antioxidants such as HT and γ-oryzanol, menthol,
It is a substance used in flavorings such as Zionell and rose oil, foods and health foods, cosmetics, and pharmaceuticals. More preferably, fat-soluble vitamins such as vitamins A, D, E, and K, or a mixture thereof. The content of fat-soluble substance is usually 1
4040%, preferably 5-30%.
【０００７】本発明において乳化剤とは、ラウリン酸デ
カグリセリル、ミリスチン酸デカグリセリル、パルミチ
ン酸デカグリセリル、ステアリン酸デカグリセリル、ア
ラキン酸デカグリセリル、ベヘン酸デカグリセリル、カ
プロレイン酸デカグリセリル、ラウロレイン酸デカグリ
セリル、ミリストレイン酸デカグリセリル、パルミトレ
イン酸デカグリセリル、オレイン酸デカグリセリル、バ
クセン酸デカグリセリル、リシノレイン酸デカグリセリ
ル、ガドレイン酸デカグリセリル、リノール酸デカグリ
セリル、リノレン酸デカグリセリル、アラキドン酸デカ
グリセリル等のポリグリセリン脂肪酸エステル、レシチ
ン、リゾレシチン、ヒドロキシル化レシチン、ケファリ
ン、リゾケファリン、プラスマローゲン等のグリセロリ
ン脂質、ショ糖脂肪酸エステル、ポリオキシエチレンソ
ルビタン脂肪酸エステル等のポリオール系界面活性剤、
ポリオキシエチレン硬化ヒマシ油等のポリオキシエチレ
ン系界面活性剤、サポニン、シニグリン、ヘスペリジ
ン、セレブロシド等の配糖体等を意味する。好ましくは
ステアリン酸デカグリセリル、オレイン酸デカグリセリ
ル、レシチンおよびリゾレシチンである。なお、上記の
ポリグリセリン脂肪酸エステルは、モノエステル、ジエ
ステル、トリエステルのうち１〜３種の混合物が好まし
く、モノエステルにジエステル及び／又はトリエステル
を混合したものがさらに好ましい。これら乳化剤の含有
量は、通常3〜50％、好ましくは5〜30％である。In the present invention, the emulsifier includes decaglyceryl laurate, decaglyceryl myristate, decaglyceryl palmitate, decaglyceryl stearate, decaglyceryl arachiate, decaglyceryl behenate, decaglyceryl caproleate, decaglyceryl laurooleate, Polyglycerol fatty acids such as decaglyceryl myristoleate, decaglyceryl palmitoleate, decaglyceryl oleate, decaglyceryl vaccenate, decaglyceryl ricinoleate, decaglyceryl gadolinate, decaglyceryl linoleate, decaglyceryl linolenate, and decaglyceryl arachidonate Glycerophospholipids such as esters, lecithin, lysolecithin, hydroxylated lecithin, kephalin, lysokephalin, plasmalogen, and sucrose fat Esters, polyol based surfactants such as polyoxyethylene sorbitan fatty acid esters,
Polyoxyethylene surfactants such as polyoxyethylene hydrogenated castor oil, and glycosides such as saponin, sinigrin, hesperidin, cerebroside and the like. Preferred are decaglyceryl stearate, decaglyceryl oleate, lecithin and lysolecithin. The above-mentioned polyglycerin fatty acid ester is preferably a mixture of one to three kinds among monoesters, diesters and triesters, and more preferably a mixture of monoesters with diesters and / or triesters. The content of these emulsifiers is usually 3 to 50%, preferably 5 to 30%.
【０００８】また、多価アルコールとしては、グリセリ
ン、ジグリセリン、トリグリセリン、ポリグリセリン、
プロピレングリコール、ジプロピレングリコール、1,3
−ブチレングリコール、エチレングリコール、ポリエチ
レグリコール、ソルビトール、キシリトール、マルチト
ール、エリスリトール、マンニトール、キシロース、グ
ルコース、ラクトース、マンノース等を使用することが
できる。好ましくは糖アルコールである。これら多価ア
ルコールの含有量は、通常10〜90％、好ましくは30〜85
％である。これら多価アルコールは市販されている物を
使用すればよい。例えば、本発明において使用したD-ソ
ルビトール液、還元麦芽糖糖水飴液は約60〜80％の固形
物と約20〜40％の水を含む液である。The polyhydric alcohols include glycerin, diglycerin, triglycerin, polyglycerin,
Propylene glycol, dipropylene glycol, 1,3
-Butylene glycol, ethylene glycol, polyethylene glycol, sorbitol, xylitol, maltitol, erythritol, mannitol, xylose, glucose, lactose, mannose and the like can be used. Preferably, it is a sugar alcohol. The content of these polyhydric alcohols is usually 10 to 90%, preferably 30 to 85%.
%. As these polyhydric alcohols, commercially available products may be used. For example, the D-sorbitol solution and reduced maltose syrup used in the present invention are liquids containing about 60-80% solids and about 20-40% water.
【０００９】均一化する際に使用できるミキサーとして
は、ホモミキサー、ホモジェッター、ポリトロンホモジ
ナイザー、クレアミックス、ヒスコトロン等の高速攪拌
機、プロペラ攪拌機、タービン攪拌機、コロイドミル、
加圧乳化機等が挙げられる。均一化および高圧処理する
際の温度範囲は、通常は常温から約90℃であり、好まし
くは60〜80℃である。また、高圧処理時の圧力範囲は限
定されないが、通常は100〜5000kg/cm2であり、好まし
くは500〜2000kg/cm2、さらに好ましくは750〜1800kg/c
m2である。Mixers which can be used for homogenization include a high-speed stirrer such as a homomixer, a homojetter, a polytron homogenizer, CLEARMIX, and Hiscotron, a propeller stirrer, a turbine stirrer, a colloid mill, and the like.
Pressurized emulsifiers and the like can be mentioned. The temperature range for homogenization and high-pressure treatment is usually from room temperature to about 90 ° C, preferably from 60 to 80 ° C. Also, the pressure range during the high pressure treatment is not limited, usually a 100~5000kg / cm 2, preferably 500~2000kg / cm 2, more preferably 750~1800kg / c
a m 2.
【００１０】本発明に係る脂溶性物質の水性液剤は、医
薬品、動物用医薬品、食品、健康食品、特定保険用食
品、家畜用飼料、水産用飼料、ペットフード、ドリンク
剤、抗酸化剤、化粧品配合剤、またはこれらに対する添
加物として使用することができる。その際、水性液剤を
そのまま用いることもでき、また公知の賦形剤を加え
て、固形化することもできる。医薬品として用いる場合
には、エアゾル剤、チンキ剤、エキス剤、含漱剤、洗口
液、エリキシル剤、ローション剤、点眼剤、点鼻剤、点
耳剤、造影剤、経膣剤、経腸剤、軟膏剤、錠剤、チュア
ブル剤、顆粒剤、カプセル剤、液剤、シロップ剤、ゼリ
ー剤、注射剤等とすることもできる。また、食品の例と
しては、清涼飲料水、炭酸飲料、乳飲料、果実飲料、ス
ポーツドリンク等の飲料、菓子、パン類、ハム、ベーコ
ン、ソーセージ等の食肉加工製品、マーガリン等の油脂
加工製品、こんぶ、素干品、煮干品等の水産加工品、ち
くわ、かまぼこ等の水産ねり製品、麺類、食酢、みそ、
しょうゆ等の発酵食品、さとう、はちみつ、でんぷん糖
の糖類、冷蔵・冷凍食品、半調理・調理済食品、酒類、
アイスクリーム類、経腸栄養食品などが挙げられる。化
粧品としては、香水、オーデコロン、浴用剤、制汗剤、
歯磨剤、洗口液、化粧水、乳液、クリーム等の基礎化粧
品、石鹸、皮膚洗浄料、毛髪用化粧品、ボディケア製品
等を例示することができる。The aqueous solution of a fat-soluble substance according to the present invention includes pharmaceuticals, veterinary medicines, foods, health foods, foods for specified insurance, livestock feeds, marine feeds, pet foods, drinks, antioxidants, cosmetics It can be used as a compounding agent or an additive thereto. At that time, the aqueous liquid preparation can be used as it is, or can be solidified by adding a known excipient. When used as pharmaceuticals, aerosols, tinctures, extracts, rinsing agents, mouth washes, elixirs, lotions, eye drops, nasal drops, ear drops, contrast agents, vaginals, enteral Agents, ointments, tablets, chewables, granules, capsules, liquids, syrups, jellies, injections and the like. Examples of foods include soft drinks, carbonated drinks, milk drinks, fruit drinks, drinks such as sports drinks, confectionery, breads, ham, bacon, processed meat products such as sausages, processed fats and oils products such as margarine, Processed marine products such as konbu, dried and boiled products, seafood paste products such as chikuwa and kamaboko, noodles, vinegar, miso,
Fermented foods such as soy sauce, sugar, honey, starch sugars, refrigerated / frozen foods, semi-cooked / prepared foods, alcoholic beverages,
Ice creams, enteral nutrition foods, and the like. Cosmetics include perfume, cologne, bath agents, antiperspirants,
Examples include basic cosmetics such as dentifrices, mouthwashes, lotions, emulsions, creams, soaps, skin cleansers, hair cosmetics, body care products, and the like.
【００１１】[0011]
【実施例】次に実施例を挙げて本発明を説明するが、本
発明はこれらに限定されるものではない。 実施例１ 各種ビタミンＥ水性液剤 表１に示した処方で、各成分を混合し、約70℃に加温し
ながら、ホモミキサーで10000rpm×５分間攪拌混合し
て、均一な水性液剤を調製した。この水性液剤を高圧乳
化機を使用して、1000kg/cm2で高圧処理を行い、ミック
ストコフェロール水性液剤を得た。ミックストコフェロ
ールとして、E mix A40（商品名、エーザイ(株)製、以
下ミックストコフェロールと表記）、その他の成分は市
販のものを用いた。これらの高圧乳化処理液を、精製水
または酸溶液（0.75％酒石酸-酒石酸ナトリウム緩衝
液、pH3）で、ビタミンＥとして0.01％の濃度になるよ
うに希釈し、640nmにおける透過率を測定した。また、
それぞれの希釈液について、90℃で３分間の加熱処理を
行った後の透過率、45℃で１カ月間静置した後の透過率
も測定した。その結果、いずれの処方においても良好な
透過率を示した（表１）。The present invention will be described below with reference to examples, but the present invention is not limited to these examples. Example 1 Various Vitamin E Aqueous Liquid Formulations The ingredients shown in Table 1 were mixed and stirred and mixed with a homomixer at 10,000 rpm for 5 minutes while heating to about 70 ° C. to prepare a uniform aqueous liquid formulation. . This aqueous solution was subjected to high-pressure treatment at 1000 kg / cm 2 using a high-pressure emulsifier to obtain an aqueous solution of mixed tocopherol. As mixed tocopherol, E mix A40 (trade name, manufactured by Eisai Co., Ltd .; hereinafter, referred to as mixed tocopherol) and other components were commercially available. These high-pressure emulsified liquids were diluted with purified water or an acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% as vitamin E, and the transmittance at 640 nm was measured. Also,
For each of the diluents, the transmittance after heating at 90 ° C. for 3 minutes and the transmittance after standing at 45 ° C. for one month were also measured. As a result, good transmittance was shown in all the formulations (Table 1).
【００１２】[0012]
【表１】 [Table 1]
【００１３】次に、高圧処理を実施せず作製したビタミ
ンＥ水性液剤の透過率を、比較例として以下に掲げる。 比較例１ 表２に示した処方で、各成分を混合し、約70℃に加温し
ながら、ホモミキサーで10000rpm×５分間攪拌混合し
て、均一な水性液剤を調製した。これらの水性液剤を、
精製水または酸溶液（0.75％酒石酸-酒石酸ナトリウム
緩衝液、pH3）でビタミンＥとして0.01％の濃度になる
ように希釈し、640nmにおける透過率を測定した。ま
た、それぞれの希釈液について、90℃で３分間の加熱処
理を行った後の透過率も測定した。その結果、いずれの
処方においても実施例１の処方と比較して、透過率は低
くなる傾向を示した（表２）。Next, the transmittance of a vitamin E aqueous solution prepared without high-pressure treatment is shown below as a comparative example. Comparative Example 1 The components shown in Table 2 were mixed, and the mixture was stirred and mixed with a homomixer at 10,000 rpm for 5 minutes while heating at about 70 ° C. to prepare a uniform aqueous liquid preparation. These aqueous liquids,
It was diluted with purified water or an acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% as vitamin E, and the transmittance at 640 nm was measured. Further, the transmittance of each of the diluted solutions after the heat treatment at 90 ° C. for 3 minutes was also measured. As a result, in each of the formulations, the transmittance tended to be lower than that of the formulation of Example 1 (Table 2).
【００１４】[0014]
【表２】 [Table 2]
【００１５】以下に各種脂溶性薬物を使用した際の水性
液剤の例と、組成成分や作製条件の違いによる影響等の
例を掲げる。 実施例２ 各種ビタミン水性液剤 表３に示した処方で実施例１と同様の方法を用いて、各
種ビタミンの水性液剤を得た。これらの液剤について、
精製水または酸溶液（0.75％酒石酸-酒石酸ナトリウム
緩衝液、pH3）で、それぞれのビタミンとして0.01％の
濃度になるように希釈し、640nmにおける透過率を測定
した。また、それぞれの希釈液について、90℃で３分間
の加熱処理を行った後の透過率も測定した。その結果、
各種ビタミン水性液剤の透過率は、いずれの処方におい
ても良好であった（表３）。The following are examples of aqueous solutions when various fat-soluble drugs are used, and examples of the effects of differences in composition components and preparation conditions. Example 2 Aqueous solutions of various vitamins Using the same method as in Example 1 with the formulations shown in Table 3, aqueous solutions of various vitamins were obtained. For these liquids,
Each vitamin was diluted with purified water or an acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% for each vitamin, and the transmittance at 640 nm was measured. Further, the transmittance of each of the diluted solutions after the heat treatment at 90 ° C. for 3 minutes was also measured. as a result,
The permeability of various aqueous vitamin solutions was good in any of the formulations (Table 3).
【００１６】[0016]
【表３】 [Table 3]
【００１７】実施例３ 各種脂溶性薬物の水性液剤 表４に示した処方で実施例１と同様の方法を用いて、各
種脂溶性薬物の水性液剤を得た。これらの液剤につい
て、精製水または酸溶液（0.75％酒石酸-酒石酸ナトリ
ウム緩衝液、pH3）でそれぞれの薬物（処方13は大豆
油）として0.01％の濃度になるように希釈し、640nmに
おける透過率を測定した。また、それぞれの希釈液につ
いて、90℃で３分間の加熱処理を行った後の透過率も測
定した。その結果、各種脂溶性薬物水性液剤の透過率
は、いずれの処方の場合にも良好であった（表４）。Example 3 Aqueous solutions of various fat-soluble drugs Using the same method as in Example 1 with the formulations shown in Table 4, aqueous solutions of various fat-soluble drugs were obtained. These solutions were diluted with purified water or an acid solution (0.75% tartaric acid-sodium tartrate buffer, pH 3) to a concentration of 0.01% for each drug (formulation 13 was soybean oil), and the transmittance at 640 nm was measured. It was measured. Further, the transmittance of each of the diluted solutions after the heat treatment at 90 ° C. for 3 minutes was also measured. As a result, the transmittance of various aqueous solutions of fat-soluble drugs was good in any of the formulations (Table 4).
【００１８】[0018]
【表４】 [Table 4]
【００１９】実施例４ 処理圧力の違いによる透過率へ
の影響 表５に示した処方で実施例１と同様の方法を用いて、ミ
ックストコフェロールの水性液剤を得た。これらの液剤
について、精製水でトコフェロールとして0.01％の濃度
になるように希釈し、640nmにおける透過率を測定し
た。処理圧力は300、500、750、1000、1500および1800k
g/cm2とした。その結果、500kg/cm2以上の圧力で処理す
ると好ましい結果が得られ、特に750kg/cm2以上の圧力
で処理したものは、透過率が極めて良好であった。Example 4 Effect of Different Processing Pressures on Permeability Using the same method as in Example 1 with the formulation shown in Table 5, an aqueous solution of mixed tocopherol was obtained. These solutions were diluted with purified water to a concentration of 0.01% as tocopherol, and the transmittance at 640 nm was measured. Processing pressures 300, 500, 750, 1000, 1500 and 1800k
g / cm 2 . As a result, favorable results were obtained when the treatment was carried out at a pressure of 500 kg / cm 2 or more, and those treated at a pressure of 750 kg / cm 2 or more had extremely good transmittance.
【００２０】[0020]
【表５】 [Table 5]
【００２１】実施例５ 脂肪酸鎖種の違いによる透過率
への影響 表６に示した処方で実施例１と同様の方法を用いて、ミ
ックストコフェロールの水性液剤を得た。これらの液剤
について、精製水または酸溶液（0.75％酒石酸-酒石酸
ナトリウム緩衝液、pH3）でそれぞれビタミンＥとして
0.01％の濃度になるように希釈し、640nmにおける透過
率を測定した。また、それぞれの希釈液について、90℃
で３分間の加熱処理を行った後の透過率も測定した。そ
の結果、脂肪酸鎖としてステアリン酸またはオレイン酸
を使用したときには、液性、加熱処理に関係なく透過率
は良好であった。ミリスチン酸またはラウリン酸を使用
したときには、精製水で希釈したとき（加熱処理時を含
む）および酸溶液で希釈した直後の透過率は良好であっ
たが、酸溶液で希釈し、90℃で加熱処理をした場合には
透過率は低下する傾向を示した（表６）。Example 5 Influence of Different Fatty Acid Chain Types on Permeability The aqueous solution of mixed tocopherol was obtained using the formulation shown in Table 6 and the same method as in Example 1. Each of these solutions is purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH3) as vitamin E.
After dilution to a concentration of 0.01%, the transmittance at 640 nm was measured. For each diluent, 90 ° C
The transmittance after the heat treatment for 3 minutes was also measured. As a result, when stearic acid or oleic acid was used as the fatty acid chain, the transmittance was good regardless of the liquid property and the heat treatment. When using myristic acid or lauric acid, the transmittance was good when diluted with purified water (including during heat treatment) and immediately after dilution with an acid solution, but diluted with an acid solution and heated at 90 ° C. When treated, the transmittance tended to decrease (Table 6).
【００２２】[0022]
【表６】 [Table 6]
【００２３】実施例６ レシチンまたはリゾレシチンを
用いたビタミンＥ水性液剤 表７に示した処方で実施例１と同様の方法を用いて、ミ
ックストコフェロールの水性液剤を得た。これらの液剤
について、精製水または酸溶液（0.75％酒石酸-酒石酸
ナトリウム緩衝液、pH3）でそれぞれビタミンＥとして
0.01％の濃度になるように希釈し、640nmにおける透過
率を測定した。また、それぞれの希釈液について、90℃
で３分間の加熱処理を行った後の透過率も測定した。そ
の結果、いずれの処方においても透過率は良好であった
（表７）。Example 6 Aqueous solution of vitamin E using lecithin or lysolecithin An aqueous solution of mixed tocopherol was obtained by the same method as in Example 1 using the formulation shown in Table 7. Each of these solutions is purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH3) as vitamin E.
After dilution to a concentration of 0.01%, the transmittance at 640 nm was measured. For each diluent, 90 ° C
The transmittance after the heat treatment for 3 minutes was also measured. As a result, the transmittance was good in each of the formulations (Table 7).
【００２４】[0024]
【表７】 [Table 7]
【００２５】実施例７ 多価アルコールの違いによる透
過率への影響 表８に示した処方で実施例１と同様の方法を用いて、ミ
ックストコフェロールの水性液剤を得た。これらの液剤
について、精製水または酸溶液（0.75％酒石酸-酒石酸
ナトリウム緩衝液、pH3）でそれぞれビタミンＥとして
0.01％の濃度になるように希釈し、640nmにおける透過
率を測定した。また、それぞれの希釈液について、90℃
で３分間の加熱処理を行った後の透過率も測定した。そ
の結果、いずれの処方においても透過率は良好であった
（表８）。Example 7 Effect of Difference in Polyhydric Alcohol on Permeability Using the same method as in Example 1 with the formulation shown in Table 8, an aqueous solution of mixed tocopherol was obtained. Each of these solutions is purified water or acid solution (0.75% tartaric acid-sodium tartrate buffer, pH3) as vitamin E.
After dilution to a concentration of 0.01%, the transmittance at 640 nm was measured. For each diluent, 90 ° C
The transmittance after the heat treatment for 3 minutes was also measured. As a result, the transmittance was good in each of the formulations (Table 8).
【００２６】[0026]
【表８】 [Table 8]
【００２７】実施例８ 官能試験 表９および10に示した処方で実施例１と同様の方法を用
いて、ミックストコフェロールの水性液剤を得た。ま
た、表11に示した処方の市販品のビタミンＥ製剤を用意
した。これらの液剤を、精製水または市販のドリンク剤
で、それぞれビタミンＥとして0.01％の濃度になるよう
に希釈し、官能試験に供した。４人の熟練したパネラー
が、約20mlの各希釈液を約５秒間口に含んで吐き出し、
味と香りを以下の４段階で評価した。◎：製品の風味に
影響を与えない。○：製品の風味に対する影響は少な
い。△：製品の風味に影響を与える。×：製品の風味に
影響を与え、飲料用として適さない。その結果を表９、
10および11に示した。Example 8 Sensory test An aqueous solution of mixed tocopherol was obtained by the same method as in Example 1 using the formulations shown in Tables 9 and 10. Also, a commercially available vitamin E preparation having the formulation shown in Table 11 was prepared. These liquid preparations were diluted with purified water or a commercially available drink preparation to a concentration of 0.01% as vitamin E, respectively, and subjected to a sensory test. Four skilled panelists exhale about 20 ml of each diluent in their mouth for about 5 seconds,
The taste and aroma were evaluated on the following four scales. ：: Does not affect the flavor of the product. ：: The influence on the flavor of the product is small. Δ: affects the flavor of the product. ×: Influences the flavor of the product and is not suitable for beverages. Table 9 shows the results.
Indicated in 10 and 11.
【００２８】[0028]
【表９】 [Table 9]
【００２９】[0029]
【表１０】 [Table 10]
【００３０】[0030]
【表１１】 [Table 11]
Claims (26)
コールおよび水を攪拌混合した後、高圧処理することを
特徴とする脂溶性物質水性液剤。1. An aqueous solution of a fat-soluble substance, which comprises subjecting one or more fat-soluble substances, an emulsifier, a polyhydric alcohol and water to stirring and mixing, followed by high-pressure treatment.
量部の乳化剤、30〜85％重量部の多価アルコールを含む
ことを特徴とする請求項１記載の脂溶性物質水性液剤。2. The fat-soluble substance according to claim 1, which comprises 5 to 30% by weight of a fat-soluble substance, 5 to 30% by weight of an emulsifier, and 30 to 85% by weight of a polyhydric alcohol. Aqueous liquid preparation.
量部の乳化剤、30〜85％重量部の多価アルコールおよび
水をミキサーで攪拌混合した後に、高圧ホモジナイザー
を用いて500〜2000kg/cm2で処理することを特徴とする
請求項１記載の脂溶性物質水性液剤。3. A mixture of 5 to 30% by weight of a fat-soluble substance, 5 to 30% by weight of an emulsifier, 30 to 85% by weight of a polyhydric alcohol and water is stirred and mixed with a mixer, and then mixed with a high-pressure homogenizer. 2. The aqueous solution of a fat-soluble substance according to claim 1, wherein the aqueous solution is treated at 500 to 2000 kg / cm < 2 >.
量部の乳化剤、30〜85％重量部の多価アルコールおよび
水をミキサーで攪拌混合した後、高圧ホモジナイザーを
用いて750〜1800kg/cm2で処理することを特徴とする請
求項１記載の脂溶性物質水性液剤。4. A mixture of 5 to 30% by weight of a fat-soluble substance, 5 to 30% by weight of an emulsifier, 30 to 85% by weight of a polyhydric alcohol and water with stirring by a mixer, and then using a high-pressure homogenizer. 2. The aqueous solution of a fat-soluble substance according to claim 1, wherein the aqueous solution is treated at 750 to 1800 kg / cm < 2 >.
び油脂から選ばれる１種以上である請求項１〜４のいず
れかに記載の脂溶性物質水性液剤。5. The aqueous solution of a fat-soluble substance according to claim 1, wherein the fat-soluble substance is at least one selected from fat-soluble drugs, vitamins and fats and oils.
ムＱ10、ビタミン類がビタミンＡ、Ｄ、ＥおよびＫ、ま
たはそれらの誘導体から選ばれる１種以上、油脂が精
油、植物油、動物油、脂溶性色素、香料またはβ−カロ
チンである請求項５記載の脂溶性物質水性液剤。6. The fat-soluble drug is teprenone or coenzyme Q 10 , the vitamins are at least one selected from vitamins A, D, E and K, or derivatives thereof, and the fats and oils are essential oils, vegetable oils, animal oils, fat-soluble pigments, The fat-soluble substance aqueous solution according to claim 5, which is a fragrance or β-carotene.
たは６に記載の脂溶性物質水性液剤。7. The aqueous solution of a fat-soluble substance according to claim 5, wherein the vitamin is vitamin E.
よび／またはグリセロリン脂質である請求項１〜４のい
ずれかに記載の脂溶性物質水性液剤。8. The aqueous solution of a fat-soluble substance according to claim 1, wherein the emulsifier is a polyglycerol fatty acid ester and / or glycerophospholipid.
ン酸デカグリセリル、グリセロリン脂質がレシチンおよ
び／またはリゾレシチンである請求項８記載の脂溶性物
質水性液剤。9. The aqueous solution of a fat-soluble substance according to claim 8, wherein the polyglycerin fatty acid ester is decaglyceryl stearate and the glycerophospholipid is lecithin and / or lysolecithin.
求項１〜４のいずれかに記載の脂溶性物質水性液剤。10. The aqueous solution of a fat-soluble substance according to claim 1, wherein the polyhydric alcohol is a sugar alcohol.
はソルビトールである請求項１０記載の脂溶性物質水性
液剤。11. The aqueous solution of a fat-soluble substance according to claim 10, wherein the sugar alcohol is glycerin and / or sorbitol.
がステアリン酸デカグリセリル、レシチンおよびリゾレ
シチンから選ばれる１種以上、多価アルコールがソルビ
トールおよび／またはグリセリンである請求項１〜４の
いずれかに記載の脂溶性物質水性液剤。12. The method according to claim 1, wherein the fat-soluble substance is vitamin E, the emulsifier is at least one selected from decaglyceryl stearate, lecithin and lysolecithin, and the polyhydric alcohol is sorbitol and / or glycerin. 3. The aqueous solution of a fat-soluble substance according to item 1.
がステアリン酸デカグリセリル、ショ糖脂肪酸エステ
ル、レシチン、リゾレシチン、ポリオキシエチレンソル
ビタン脂肪酸エステル、ポリオキシエチレン硬化ヒマシ
油およびサポニンから選ばれる１種以上、多価アルコー
ルがソルビトールおよび／またはグリセリンである請求
項１〜４のいずれかに記載の脂溶性物質水性液剤。13. The fat-soluble substance is vitamin E, and the emulsifier is one selected from decaglyceryl stearate, sucrose fatty acid ester, lecithin, lysolecithin, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil and saponin. As described above, the aqueous solution of a fat-soluble substance according to any one of claims 1 to 4, wherein the polyhydric alcohol is sorbitol and / or glycerin.
ルコールおよび水を攪拌混合した後、高圧処理すること
を特徴とする脂溶性物質水性液剤の製造方法。14. A method for producing an aqueous solution of a fat-soluble substance, which comprises subjecting one or more fat-soluble substances, an emulsifier, a polyhydric alcohol and water to stirring and mixing, followed by high-pressure treatment.
重量部の乳化剤、30〜85％重量部の多価アルコールを含
むことを特徴とする請求項１４記載の脂溶性物質水性液
剤の製造方法。15. A fat-soluble substance of 5 to 30% by weight, 5 to 30%
The method for producing an aqueous solution of a fat-soluble substance according to claim 14, wherein the aqueous solution contains fat parts by weight of emulsifier and 30 to 85% by weight of polyhydric alcohol.
重量部の乳化剤、30〜85％重量部の多価アルコールおよ
び水をミキサーで攪拌混合した後に、高圧ホモジナイザ
ーを用いて500〜2000kg/cm2で処理することを特徴とす
る請求項１４記載の脂溶性物質水性液剤の製造方法。16. A fat-soluble substance of 5 to 30% by weight, 5 to 30%
Emulsifier parts, after stirring and mixing in a mixer the polyhydric alcohol and water of 30% to 85% parts by weight, fat of claim 14, wherein the treatment with 500~2000kg / cm 2 using a high-pressure homogenizer A method for producing an aqueous solution of a soluble substance.
重量部の乳化剤、30〜85％重量部の多価アルコールおよ
び水をミキサーで攪拌混合した後、高圧ホモジナイザー
を用いて750〜1800kg/cm2で処理することを特徴とする
請求項１４記載の脂溶性物質水性液剤の製造方法。17. 5 to 30% by weight of fat-soluble substance, 5 to 30%
Emulsifier parts by weight was stirred and mixed by a mixer polyhydric alcohol and water of 30% to 85% parts by weight, fat of claim 14, wherein the treatment with 750~1800kg / cm 2 using a high-pressure homogenizer A method for producing an aqueous solution of a soluble substance.
よび油脂から選ばれるれる１種以上である請求項１４〜
１７のいずれかに記載の脂溶性物質水性液剤の製造方
法。18. The fat-soluble substance is at least one selected from fat-soluble drugs, vitamins and fats and oils.
18. The method for producing an aqueous liquid solution of a fat-soluble substance according to any one of 17.
イムＱ10、ビタミン類がビタミンＡ、Ｄ、ＥおよびＫ、
またはそれらの誘導体から選ばれる１種以上、油脂が精
油、植物油、動物油、脂溶性色素、香料またはβ−カロ
チンである請求項１８記載の脂溶性物質水性液剤の製造
方法。19. The fat-soluble drug is teprenone or coenzyme Q 10 , and the vitamins are vitamins A, D, E and K.
19. The method for producing an aqueous solution of a fat-soluble substance according to claim 18, wherein the fat or oil selected from the group consisting of one or more derivatives thereof is an essential oil, a vegetable oil, an animal oil, a fat-soluble pigment, a flavor, or β-carotene.
８または１９に記載の脂溶性物質水性液剤の製造方法。20. The method according to claim 1, wherein the vitamins are vitamin E.
20. The method for producing an aqueous solution of a fat-soluble substance according to 8 or 19.
および／またはグリセロリン脂質である請求項１４〜１
７のいずれかに記載の脂溶性物質水性液剤の製造方法。21. The method according to claim 14, wherein the emulsifier is a polyglycerin fatty acid ester and / or glycerophospholipid.
8. The method for producing an aqueous solution of a fat-soluble substance according to any one of 7.
リン酸デカグリセリル、グリセロリン脂質がレシチンお
よび／またはリゾレシチンである請求項２１記載の脂溶
性物質水性液剤の製造方法。22. The method according to claim 21, wherein the polyglycerin fatty acid ester is decaglyceryl stearate and the glycerophospholipid is lecithin and / or lysolecithin.
求項１４〜１７のいずれかに記載の脂溶性物質水性液剤
の製造方法。23. The method for producing an aqueous solution of a fat-soluble substance according to claim 14, wherein the polyhydric alcohol is a sugar alcohol.
はソルビトールである請求項２３記載の脂溶性物質水性
液剤の製造方法。24. The method for producing an aqueous solution of a fat-soluble substance according to claim 23, wherein the sugar alcohol is glycerin and / or sorbitol.
がステアリン酸デカグリセリル、レシチンおよびリゾレ
シチンから選ばれる１種以上、多価アルコールがソルビ
トールおよび／またはグリセリンである請求項１４〜１
７のいずれかに記載の脂溶性物質水性液剤の製造方法。25. The method according to claim 14, wherein the fat-soluble substance is vitamin E, the emulsifier is at least one selected from decaglyceryl stearate, lecithin and lysolecithin, and the polyhydric alcohol is sorbitol and / or glycerin.
8. The method for producing an aqueous solution of a fat-soluble substance according to any one of 7.
がステアリン酸デカグリセリル、ショ糖脂肪酸エステ
ル、レシチン、リゾレシチン、ポリオキシエチレンソル
ビタン脂肪酸エステル、ポリオキシエチレン硬化ヒマシ
油およびサポニンから選ばれる１種以上、多価アルコー
ルがソルビトールおよび／またはグリセリンである請求
項１４〜１７のいずれかに記載の脂溶性物質水性液剤の
製造方法。26. The fat-soluble substance is vitamin E, and the emulsifier is one selected from decaglyceryl stearate, sucrose fatty acid ester, lecithin, lysolecithin, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil and saponin. The method for producing an aqueous solution of a fat-soluble substance according to any one of claims 14 to 17, wherein the polyhydric alcohol is sorbitol and / or glycerin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32519299A JP3880265B2 (en) | 1998-11-16 | 1999-11-16 | Aqueous solution of fat-soluble substances |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10-325662 | 1998-11-16 | ||
| JP32566298 | 1998-11-16 | ||
| JP32519299A JP3880265B2 (en) | 1998-11-16 | 1999-11-16 | Aqueous solution of fat-soluble substances |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000212066A true JP2000212066A (en) | 2000-08-02 |
| JP3880265B2 JP3880265B2 (en) | 2007-02-14 |
Family
ID=26571758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP32519299A Expired - Fee Related JP3880265B2 (en) | 1998-11-16 | 1999-11-16 | Aqueous solution of fat-soluble substances |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3880265B2 (en) |
Cited By (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002338499A (en) * | 2001-05-17 | 2002-11-27 | Bs Lab:Kk | Skin care preparation for external use |
| JP2004131443A (en) * | 2002-10-11 | 2004-04-30 | Kobayashi Pharmaceut Co Ltd | Liquid external preparation and method for producing the same |
| WO2004050072A1 (en) * | 2002-12-04 | 2004-06-17 | Nisshin Pharma Inc. | Water-soluble composition containing coenzyme q10 |
| JP2004196781A (en) * | 2002-12-04 | 2004-07-15 | Nof Corp | Water-soluble composition containing coenzyme q10 |
| JP2004261005A (en) * | 2003-01-17 | 2004-09-24 | Taiyo Kagaku Co Ltd | Ubidecarenone preparation |
| WO2005034913A1 (en) * | 2003-10-10 | 2005-04-21 | Eisai Co., Ltd. | Novel liquid preparation composition |
| JP2005194267A (en) * | 2003-12-10 | 2005-07-21 | Kao Corp | Method for production of oil-in-water type emulsified composition |
| JP2006056816A (en) * | 2004-08-19 | 2006-03-02 | Nof Corp | Fat-soluble vitamins-containing pre-emulsion |
| JP2006141247A (en) * | 2004-11-17 | 2006-06-08 | Nisshin Pharma Inc | Medium composition for cell culture containing coenzyme q10 |
| JP2006143651A (en) * | 2004-11-19 | 2006-06-08 | Cosmetics Roorando Kk | Water-soluble cosmetic and food |
| JP2006290841A (en) * | 2005-04-14 | 2006-10-26 | Nippon Zettoc Co Ltd | Method for producing cosmetic and cosmetic |
| JP2006306879A (en) * | 2002-12-04 | 2006-11-09 | Nof Corp | Method for producing water-soluble composition containing coenzyme q10 |
| WO2006134970A1 (en) * | 2005-06-15 | 2006-12-21 | Kaneka Corporation | Coenzyme q10-containing water-soluble composition and process for production thereof |
| JP2007015965A (en) * | 2005-07-06 | 2007-01-25 | Besubio:Kk | Water-soluble composition containing ubiquinones |
| JP2007135439A (en) * | 2005-11-16 | 2007-06-07 | Nippon Flour Mills Co Ltd | Method for producing menthol-containing noodle |
| WO2007080787A1 (en) * | 2006-01-12 | 2007-07-19 | Nisshin Pharma Inc. | Coenzyme q10-containing water-soluble compositions |
| JP2007209251A (en) * | 2006-02-09 | 2007-08-23 | Taiyo Kagaku Co Ltd | Coenzyme q10-containing composition |
| JPWO2006022187A1 (en) * | 2004-08-24 | 2008-05-08 | 日清ファルマ株式会社 | Coenzyme Q10-containing composition |
| JPWO2006030850A1 (en) * | 2004-09-15 | 2008-05-15 | 三栄源エフ・エフ・アイ株式会社 | Method for preparing solubilized product of fat-soluble component |
| JP2008136487A (en) * | 2006-11-08 | 2008-06-19 | Givaudan Sa | Transparent emulsified composition and transparent emulsified flavor composition for alcoholic drinks or carbonated drinks |
| JP2008184385A (en) * | 2007-01-26 | 2008-08-14 | Ezaki Glico Co Ltd | Dispersed hesperetin |
| WO2009001786A1 (en) | 2007-06-22 | 2008-12-31 | Kaneka Corporation | Composition containing physiologically active substance |
| WO2009001787A1 (en) | 2007-06-22 | 2008-12-31 | Kaneka Corporation | Composition containing coenzyme q10 |
| WO2009022798A2 (en) * | 2007-07-26 | 2009-02-19 | Daewoong Pharmaceutical Co., Ltd. | Self-microemulsifying drug delivery system composition containing coenzyme q10 and method for preparing the same |
| WO2009029046A1 (en) * | 2007-08-29 | 2009-03-05 | Agency For Science, Technology And Research | Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use |
| WO2009078245A1 (en) * | 2007-12-19 | 2009-06-25 | Foodtech Trading Co., Ltd. | Transparent emulsified composition and cosmetic and food containing the same |
| JP2009207383A (en) * | 2008-03-03 | 2009-09-17 | T Hasegawa Co Ltd | Emulsion composition for coenzyme q10-containing beverage, and method for producing the same |
| JP2010030967A (en) * | 2008-07-30 | 2010-02-12 | Ezaki Glico Co Ltd | Dispersed hesperetin |
| JP2010227004A (en) * | 2009-03-27 | 2010-10-14 | Nof Corp | Oil-in-water edible emulsified composition |
| JP4970546B2 (en) * | 2007-10-03 | 2012-07-11 | アサヒグループホールディングス株式会社 | Granules, tablets and methods for producing them |
| WO2013183778A1 (en) * | 2012-06-08 | 2013-12-12 | ライオン株式会社 | Composition for mucous membranes |
| JP2014098014A (en) * | 2014-01-31 | 2014-05-29 | Agency For Science Technology & Research | Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use |
| US8758743B2 (en) | 2003-01-17 | 2014-06-24 | Taiyo Kagaku Co., Ltd. | Compositions containing coenzyme Q10 |
| JP2014114247A (en) * | 2012-12-11 | 2014-06-26 | Capsugel Belgium Nv | Oil-in-water type emulsion and method for producing the same |
| JP5588048B1 (en) * | 2013-06-17 | 2014-09-10 | 高田香料株式会社 | Emulsified fragrance composition |
| US8961958B2 (en) | 2004-11-16 | 2015-02-24 | Bioavailability, Inc | High concentration self-microemulsifying coenzyme Q10 preparations for nutritional use |
| KR101508375B1 (en) | 2007-12-19 | 2015-04-03 | (주)뉴트리 | Transparent emulsified composition and cosmetics or food comprising the same |
| TWI565464B (en) * | 2012-02-27 | 2017-01-11 | 樂敦製藥股份有限公司 | Ophthalmic composition |
| WO2017022811A1 (en) * | 2015-08-04 | 2017-02-09 | 日東薬品工業株式会社 | Emulsion composition for preventing or ameliorating snoring |
| JP2018043990A (en) * | 2017-10-11 | 2018-03-22 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ | Oil-in-water emulsion and method for producing the same |
-
1999
- 1999-11-16 JP JP32519299A patent/JP3880265B2/en not_active Expired - Fee Related
Cited By (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002338499A (en) * | 2001-05-17 | 2002-11-27 | Bs Lab:Kk | Skin care preparation for external use |
| JP4615814B2 (en) * | 2002-10-11 | 2011-01-19 | 小林製薬株式会社 | Liquid external preparation for cold medicine and method for producing the same |
| JP2004131443A (en) * | 2002-10-11 | 2004-04-30 | Kobayashi Pharmaceut Co Ltd | Liquid external preparation and method for producing the same |
| JP2004196781A (en) * | 2002-12-04 | 2004-07-15 | Nof Corp | Water-soluble composition containing coenzyme q10 |
| US7470436B2 (en) | 2002-12-04 | 2008-12-30 | Nisshin Pharma Inc. | Water-soluble composition containing coenzyme Q10 |
| CN100337620C (en) * | 2002-12-04 | 2007-09-19 | 日清药业股份有限公司 | Water-soluble composition containing coenzyme q10 |
| JP4518042B2 (en) * | 2002-12-04 | 2010-08-04 | 日油株式会社 | Method for producing water-soluble composition containing coenzyme Q10 |
| WO2004050072A1 (en) * | 2002-12-04 | 2004-06-17 | Nisshin Pharma Inc. | Water-soluble composition containing coenzyme q10 |
| JP2006306879A (en) * | 2002-12-04 | 2006-11-09 | Nof Corp | Method for producing water-soluble composition containing coenzyme q10 |
| KR101061679B1 (en) | 2002-12-04 | 2011-09-02 | 닛신 파마 가부시키가이샤 | Water-soluble composition containing coenzyme # 10 |
| JP2004261005A (en) * | 2003-01-17 | 2004-09-24 | Taiyo Kagaku Co Ltd | Ubidecarenone preparation |
| US8758743B2 (en) | 2003-01-17 | 2014-06-24 | Taiyo Kagaku Co., Ltd. | Compositions containing coenzyme Q10 |
| JP4567945B2 (en) * | 2003-01-17 | 2010-10-27 | 太陽化学株式会社 | Ubidecarenone formulation |
| JPWO2005034913A1 (en) * | 2003-10-10 | 2006-12-21 | エーザイ株式会社 | New liquid composition |
| AU2004279225B2 (en) * | 2003-10-10 | 2009-10-29 | Mitsubishi-Chemical Foods Corporation | Novel liquid preparation composition |
| US8557259B2 (en) | 2003-10-10 | 2013-10-15 | Eisai R&D Management Co., Ltd. | Liquid preparation |
| JP4787019B2 (en) * | 2003-10-10 | 2011-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | New liquid composition |
| WO2005034913A1 (en) * | 2003-10-10 | 2005-04-21 | Eisai Co., Ltd. | Novel liquid preparation composition |
| JP2005194267A (en) * | 2003-12-10 | 2005-07-21 | Kao Corp | Method for production of oil-in-water type emulsified composition |
| JP2006056816A (en) * | 2004-08-19 | 2006-03-02 | Nof Corp | Fat-soluble vitamins-containing pre-emulsion |
| US8119113B2 (en) | 2004-08-24 | 2012-02-21 | Nisshin Pharma, Inc. | Coenzyme Q10—containing composition |
| JPWO2006022187A1 (en) * | 2004-08-24 | 2008-05-08 | 日清ファルマ株式会社 | Coenzyme Q10-containing composition |
| JP4842824B2 (en) * | 2004-08-24 | 2011-12-21 | 日清ファルマ株式会社 | Coenzyme Q10-containing composition |
| JPWO2006030850A1 (en) * | 2004-09-15 | 2008-05-15 | 三栄源エフ・エフ・アイ株式会社 | Method for preparing solubilized product of fat-soluble component |
| US8961958B2 (en) | 2004-11-16 | 2015-02-24 | Bioavailability, Inc | High concentration self-microemulsifying coenzyme Q10 preparations for nutritional use |
| JP2006141247A (en) * | 2004-11-17 | 2006-06-08 | Nisshin Pharma Inc | Medium composition for cell culture containing coenzyme q10 |
| JP2006143651A (en) * | 2004-11-19 | 2006-06-08 | Cosmetics Roorando Kk | Water-soluble cosmetic and food |
| JP2006290841A (en) * | 2005-04-14 | 2006-10-26 | Nippon Zettoc Co Ltd | Method for producing cosmetic and cosmetic |
| US8388950B2 (en) | 2005-06-15 | 2013-03-05 | Kaneka Corporation | Coenzyme Q10-containing water-soluble composition and process for production thereof |
| JP5199665B2 (en) * | 2005-06-15 | 2013-05-15 | 株式会社カネカ | Coenzyme Q10-containing water-soluble composition and process for producing the same |
| WO2006134970A1 (en) * | 2005-06-15 | 2006-12-21 | Kaneka Corporation | Coenzyme q10-containing water-soluble composition and process for production thereof |
| JP2007015965A (en) * | 2005-07-06 | 2007-01-25 | Besubio:Kk | Water-soluble composition containing ubiquinones |
| JP2007135439A (en) * | 2005-11-16 | 2007-06-07 | Nippon Flour Mills Co Ltd | Method for producing menthol-containing noodle |
| JP4662149B2 (en) * | 2005-11-16 | 2011-03-30 | 日本製粉株式会社 | Method for producing menthol-containing noodles |
| WO2007080787A1 (en) * | 2006-01-12 | 2007-07-19 | Nisshin Pharma Inc. | Coenzyme q10-containing water-soluble compositions |
| JP4644135B2 (en) * | 2006-02-09 | 2011-03-02 | 太陽化学株式会社 | Coenzyme Q10-containing composition |
| JP2007209251A (en) * | 2006-02-09 | 2007-08-23 | Taiyo Kagaku Co Ltd | Coenzyme q10-containing composition |
| JP4563438B2 (en) * | 2006-11-08 | 2010-10-13 | ジボダン エス エー | Transparent emulsified composition and transparent emulsified fragrance composition for alcoholic beverage or carbonated beverage |
| JP2008136487A (en) * | 2006-11-08 | 2008-06-19 | Givaudan Sa | Transparent emulsified composition and transparent emulsified flavor composition for alcoholic drinks or carbonated drinks |
| JP2008184385A (en) * | 2007-01-26 | 2008-08-14 | Ezaki Glico Co Ltd | Dispersed hesperetin |
| WO2009001787A1 (en) | 2007-06-22 | 2008-12-31 | Kaneka Corporation | Composition containing coenzyme q10 |
| WO2009001786A1 (en) | 2007-06-22 | 2008-12-31 | Kaneka Corporation | Composition containing physiologically active substance |
| WO2009022798A3 (en) * | 2007-07-26 | 2009-04-09 | Dae Woong Pharma | Self-microemulsifying drug delivery system composition containing coenzyme q10 and method for preparing the same |
| WO2009022798A2 (en) * | 2007-07-26 | 2009-02-19 | Daewoong Pharmaceutical Co., Ltd. | Self-microemulsifying drug delivery system composition containing coenzyme q10 and method for preparing the same |
| WO2009029046A1 (en) * | 2007-08-29 | 2009-03-05 | Agency For Science, Technology And Research | Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use |
| JP2010537977A (en) * | 2007-08-29 | 2010-12-09 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | Sugar-based surfactant microemulsion containing essential oils for cosmetic and pharmaceutical use |
| US10980888B2 (en) | 2007-08-29 | 2021-04-20 | Agency For Science, Technology And Research | Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use |
| JP4970546B2 (en) * | 2007-10-03 | 2012-07-11 | アサヒグループホールディングス株式会社 | Granules, tablets and methods for producing them |
| WO2009078245A1 (en) * | 2007-12-19 | 2009-06-25 | Foodtech Trading Co., Ltd. | Transparent emulsified composition and cosmetic and food containing the same |
| KR101508375B1 (en) | 2007-12-19 | 2015-04-03 | (주)뉴트리 | Transparent emulsified composition and cosmetics or food comprising the same |
| JP2009207383A (en) * | 2008-03-03 | 2009-09-17 | T Hasegawa Co Ltd | Emulsion composition for coenzyme q10-containing beverage, and method for producing the same |
| JP2010030967A (en) * | 2008-07-30 | 2010-02-12 | Ezaki Glico Co Ltd | Dispersed hesperetin |
| JP2010227004A (en) * | 2009-03-27 | 2010-10-14 | Nof Corp | Oil-in-water edible emulsified composition |
| TWI565464B (en) * | 2012-02-27 | 2017-01-11 | 樂敦製藥股份有限公司 | Ophthalmic composition |
| WO2013183778A1 (en) * | 2012-06-08 | 2013-12-12 | ライオン株式会社 | Composition for mucous membranes |
| JP2014114247A (en) * | 2012-12-11 | 2014-06-26 | Capsugel Belgium Nv | Oil-in-water type emulsion and method for producing the same |
| JP5588048B1 (en) * | 2013-06-17 | 2014-09-10 | 高田香料株式会社 | Emulsified fragrance composition |
| JP2015000044A (en) * | 2013-06-17 | 2015-01-05 | 高田香料株式会社 | Emulsified perfume composition |
| JP2014098014A (en) * | 2014-01-31 | 2014-05-29 | Agency For Science Technology & Research | Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use |
| WO2017022811A1 (en) * | 2015-08-04 | 2017-02-09 | 日東薬品工業株式会社 | Emulsion composition for preventing or ameliorating snoring |
| JPWO2017022811A1 (en) * | 2015-08-04 | 2018-06-14 | 日東薬品工業株式会社 | Emulsion composition for preventing or improving snoring |
| JP2018043990A (en) * | 2017-10-11 | 2018-03-22 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ | Oil-in-water emulsion and method for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3880265B2 (en) | 2007-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3880265B2 (en) | Aqueous solution of fat-soluble substances | |
| US6190680B1 (en) | Oily composition and process for producing the same | |
| EP1902633B1 (en) | Method for preparing solubilized composition containing oil-soluble substance | |
| DE60320380T2 (en) | COENZYM Q10 FORMULATIONS | |
| EP3056090A1 (en) | Oil/fat composition containing polyunsaturated fatty acid | |
| KR101116899B1 (en) | Concentrated and diluted stable oil/water emulsions | |
| JPWO2006030850A1 (en) | Method for preparing solubilized product of fat-soluble component | |
| JP4044354B2 (en) | Composition having alcohol resistance, acid resistance and salt resistance and uses | |
| JP2008143841A (en) | Composition containing highly crystalline substance | |
| JP2009027958A (en) | Emulsified substance containing astaxanthin, and method for producing the same | |
| JPH07204487A (en) | Surfactant composition | |
| JP4787019B2 (en) | New liquid composition | |
| EP3693415A1 (en) | Defoaming and/or foam suppressing method for naturally derived water soluble colorant or substance including same | |
| JP2003113393A (en) | Ceramide dispersion, method for producing the same, and application of the same | |
| JP4644135B2 (en) | Coenzyme Q10-containing composition | |
| JPH0693996B2 (en) | Emulsified composition | |
| JP2000157168A (en) | Oily composition and its production | |
| JP2004208555A (en) | Emulsifiable preparation | |
| US20060068078A1 (en) | Polyglycerin fatty acid esters and emulsified or solubilized compositions comprising them | |
| WO2014050709A1 (en) | Cosmetic and glycyrrhetinic acid derivative-containing emulsification composition | |
| JP2009013234A (en) | Powdery composition, method for producing the same, and foodstuff composition, cosmetics composition and medicinal composition containing the same | |
| JP6776175B2 (en) | Method for producing oil-in-water emulsified composition, external preparation for skin and external preparation for skin | |
| JP2006045061A (en) | Ceramides-containing composition, ceramides-containing aqueous preparation, and food and beverage, cosmetic and external preparation for skin, each containing the same composition or the same preparation | |
| JP2000024487A (en) | Emulsified composition containing oily composition | |
| JP2004154060A (en) | Phosphatidylserine solubilizing solution, method for producing the same and use of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050526 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050627 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050826 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051102 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20051208 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20060711 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061107 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |